Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 10/20 | 0.42 |
| ▸ | JAK1 | P23458 | 10/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2468693 | 0.91 | GPR119 (0.43) | HDAC2HDAC1JAK2JAK1GPR119 | |
| SCHEMBL29995192 | 0.90 | GPR119 (0.44) | HDAC2HDAC1JAK2JAK1GPR119 | |
| SCHEMBL7527349 | 0.90 | GPR119 (0.44) | HDAC2HDAC1JAK2JAK1GPR119 | |
| SCHEMBL6912571 | 0.89 | GPR119 (0.42) | HDAC2HDAC1JAK2JAK1GPR119 | |
| SCHEMBL3925930 | 0.83 | RORC (0.48) | HDAC2HDAC1JAK2JAK1RORC | |
| SCHEMBL12877871 | 0.82 | PDK2 (0.44) | HDAC1JAK2JAK1GPR119 | |
| SCHEMBL11919555 | 0.82 | GPR119 (0.44) | HDAC2HDAC1JAK2JAK1GPR119 | |
| SCHEMBL29529542 | 0.82 | GPR119 (0.45) | HDAC2HDAC1JAK2JAK1GPR119 | |
| SCHEMBL2701636 | 0.82 | GPR119 (0.45) | HDAC2HDAC1JAK2JAK1GPR119 | |
| SCHEMBL2779561 | 0.82 | GPR119 (0.43) | HDAC2HDAC1JAK2JAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488028-B1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2020-08-19 | — | — | EP | disclosed |
| CN-104945382-B | Substituted piperidines that increase p53 activity and uses thereof | 默沙东公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2014-11-13 | — | — | US | disclosed |
| US-8859776-B2 | Substituted piperidines that increase p53 activity and the uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859776-B2 | Substituted piperidines that increase p53 activity and the uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859776-B2 | Substituted piperidines that increase p53 activity and the uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2488028-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011046771-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | SCHERING CORPORATION (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | TP53, TP53BP1, MDM2 | HDAC2 191/4885HDAC1 71/4885JAK2 3297/4885 |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | TP53, MDM2, TP53BP1 | HDAC2 203/4885HDAC1 90/4885JAK2 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.